Oncopeptides joins up with Vector to commercialize blood cancer drug Pepaxto in the Middle East, North Africa

About a month af­ter On­copep­tides lost its ap­peal with the FDA to con­tin­ue the ap­proval for Pepax­to in mul­ti­ple myelo­ma pa­tients, the com­pa­ny an­nounced it’s team­ing up with Vec­tor Phar­ma to com­mer­cial­ize the drug in the Mid­dle East and North Africa.

Vec­tor will dis­trib­ute the drug, mar­ket­ed as Pepax­ti out­side of the US, in the re­gion, which in­cludes Sau­di Ara­bia, Qatar, the Unit­ed Arab Emi­rates, Bahrain, Kuwait, Oman, Al­ge­ria, Tunisia, Mo­roc­co, Libya, Lebanon and Iraq. The com­pa­nies are split­ting the rev­enues while Vec­tor will take on all of the costs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.